الفهرس 
DiscussionOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
Breast cancer is a global public burden. It is the most frequently diagnosed cancer and the leading cause of cancer death among females (Jemal et al., 2011; Bray et al., 2018). Breast cancer is a complex phenotypically diverse genetic disease, involving a variety of changes in gene expression and structure (Heneghan et al., 2009).
Hence, the search for biomarkers that could help in predicting or understanding the process of cancer is crucial, particularly for this type of cancer (Duffy et al., 2010).
Numerous studies have looked for an ideal biomarker for BC for early cancer diagnosis and prognosis prediction (Siegel et al., 2016). However, few studies have investigated the diagnostic value of plasma lncRNAs in BC and, particularly, the value of tumor monitoring has never been studied.
In about 70% of BC patients have up-regulated estrogen receptor gene expression levels which is playing an important role in breast cancer development and progression (Chang et al., 2006; Deroo, 2006). HOTAIR overexpression in various types of cancer, including breast, esophageal, lung and gastric cancer (Yang et al., 2011; Endo et al., 2013; Tang & Hann, 2018)represents a potential biomarker for diagnostic and therapeutic purposes (Zhang et al., 2015). Interestingly, The promoter of the HOTAIR gene contains multiple estrogen response elements, so it may enhance its expression in cells (Bhan et al., 2017). Prior studies revealed differential expression of miR-130a in some types of cancers as hepatocellular carcinoma, glioblastoma and leukemia (Qiu et al., 2013; Li et al., 2014; Ding et al., 2018). Deregulation of miR-130a in breast cancer is not clear and It is experimentally validated that miR-130a can act on multiple potential gene targets including ESR1 and HOTAIR genes (Li et al., 2014).
The current study was conducted to identify the expression profile of ESR1, HOTAIR, and miR-130a in the serum of Egyptian BC patients, correlate their co-expression levels with clinciopathological features, and to analyze their association with disease characteristics, aiming at determining their utility as biomarkers for predicting important prognostic and pathologic parameters in breast cancer.
In attempt to throw light on causes of their deregulation in breast cancer as there is ongoing clinical trials to use it as a new therapeutic target for cancer treatment and reversing drug resistance.